Terminated OBSERVATIONAL NCT05052372

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Sponsor: xCures

Conditions Bladder Cancer Bladder Urothelial Carcinoma FGFR Mutation FGFR2 Amplification FGFR2 Gene Mutation FGFR3 Gene Mutation Locally Advanced Urothelial Carcinoma Metastatic Urothelial Carcinoma Platinum-Resistant Urothelial Carcinoma Refractory Bladder Carcinoma Refractory Bladder Urothelial Carcinoma Transitional Cell Carcinoma Urothelial Carcinoma

Interventions Balversa

Updated 5 times since 2021 Last updated: Dec 20, 2022 Started: Nov 21, 2021 Primary completion: Dec 20, 2022 Completion: Dec 20, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor request to terminate study due to enrollment numbers

Other Bladder Cancer trials with similar outcome

Browse all Bladder Cancer trials

This observational or N/A phase trial investigates Bladder Cancer and Bladder Urothelial Carcinoma and is currently terminated or withdrawn. xCures leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated
Jul 2024 — Sep 2024 [monthly]

Terminated
Jan 2023 — Jul 2024 [monthly]

Terminated

Status: Recruiting → Terminated
Dec 2021 — Jan 2023 [monthly]

Recruiting
Oct 2021 — Dec 2021 [monthly]

Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

xCures

Data source: xCures

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Raleigh, United States